Reneuron Share Discussion Threads

[jensonbensonjohnson] 05/4/2019 14:13

Short interview with MH (CFO) here on the back of yesterday's RNS:

youtu.be/7poiamvo_FQ

[someuwin] 05/4/2019 13:41

A snippet from Edison note in Febuary

ReNeuron Group Early clinical results Exciting positive data in retinitis pigmentosa (RP)

ReNeuron has announced positive data on the first three RP patients in the Phase I/IIa clinical study of its hRPC cell therapy product. At this early stage in the study our expectations were limited as we had anticipated that more time would be required for efficacy to be seen. A surprising and dramatic improvement in visual acuity was observed – a 20-letter improvement at two months, 15- and 14-letter improvements at 18 days – in the first three patients forming the first cohort dosed with the new cryopreserved, commercially ready formulation. Investors will be familiar with the letters on an ETDRS eye chart from their regular eye tests...

...We have made no changes to our valuation or probabilities at this stage. However, we recognise that early evidence of efficacy may enable ReNeuron to advance to a pivotal study more quickly, subject to discussions with regulators. This is because, for many RP patients, no therapeutic options exist. Our forecasts and valuation are unchanged at £192m or 608p per share.

[dickbush] 05/4/2019 12:49

I agree that a new round of financing is very likely, but how many investors do you think are going to be surprised or upset if the initial success with retinitis pigmentosa continues?

My investment is still under water but I don't care because I really believe stem cells have a great future. Whether or not RENE is going to be one of the winners is yet to be decided, but it looks a lot more likely now than it did just a few weeks ago.

These small biotech companies are always a gamble. If you can't accept that you should invest somewhere else.

[someuwin] 05/4/2019 12:34

Olav Hellebø, Chief Executive Officer of ReNeuron, said:

"We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing Phase 1/2 study with our hRPC cell therapy candidate for retinitis pigmentosa. We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."

[pdt] 05/4/2019 12:33

Nightstar Therapeutics were recently purchased for £600m for their two late stage eye indications expected to generate revenue of around $500m in 2024 if all goes well.

RENE's RP treatment could also be generating a similar level of revenue in 2024 if all goes well.

So what value Rene?

[rayrac] 05/4/2019 12:28

Nice tight spread.

[masingi] 05/4/2019 11:12

Ken Chung:
The first thing is that the benefit seen is not small, it is stonkingly huge. The second point is that the benefit would be expected to be dose-dependent.

[someuwin] 05/4/2019 11:04

Buy the dip - imo.

[kwizza] 05/4/2019 10:37

What if we can all get rid of our glasses

[ken chung] 05/4/2019 10:35

Another concern is the latest trial data did not show any further improvement with time. What if the small benefit starts to decline after 6 months then back to zero.

[ken chung] 05/4/2019 10:32

That's a classic lemming and mushroom response and just exemplifies why you are one.There will be another DILUTIVE PLACING.Lemmings and mushrooms only.

[jensonbensonjohnson] 05/4/2019 10:05

No, they point to attracting investors. That's why they are called investor conferences.

[ken chung] 05/4/2019 09:58

Investor conferences point to one thing only. DILUTIVE PLACING coming soon.Lemmings and mushrooms only now.

[jensonbensonjohnson] 05/4/2019 09:15

If the efficacy continues with the 3 patients in the 1st cohort and similarly encouraging efficacy is seen in the 2nd cohort then RENE won't need to go to investment conferences because big pharma will be forming a long queue outside their door.

[city chappy] 05/4/2019 09:14

There must be takeover interest at this price.

[dickbush] 05/4/2019 09:11

Just checked their website and H C Wainwright is an American stockbroking firm. One of their research specialties is Healthcare and Life Science. So, hopefully, RENE will get greater visibility with US investors.

[top tips] 05/4/2019 09:02

Creeping back up now. Could finish today at 200p.

[top tips] 05/4/2019 09:01

More readout from the retinitis trial every few months. Company should already be priced at £400m imo.

[kwizza] 05/4/2019 08:52

wonder if there will be any further update before the investor conference

[top tips] 05/4/2019 08:33

The retinitis treatment has Fast Track and Orphan Drug status, so could be proposed for marketing approval within 12 months. Also Phase 2b stroke data readout early 2020. Obviously the company should be worth many multiples of the current £50m.

[someuwin] 05/4/2019 08:20

Still only £50m for stem cell treatments for Stroke & Blindness.

Massively undervalued - imo.

[gottopickapocketortwo] 05/4/2019 08:14

Someone with sausage fingers there has misentered that 25000 sale - should have a '1' in front of it !

[jensonbensonjohnson] 05/4/2019 07:19

A veritable media onslaught. Ha ha.

Come on RENE!!!